Alentis Therapeutics
Alentis Therapeutics is a clinical-stage biotech company developing first-in-class anti-Claudin-1 antibodies and ADCs for cancer and fibrosis. Its pipeline includes oncology candidates such as ALE.P02/ALE.P03 and the fibrosis program Lixudebart (ALE.F02).
Company facts
- Founded
- 2019
- Employees
- 67
- Headquarters
- Switzerland
- CEO
- Mark Pruzanski
About
Alentis Therapeutics is a clinical-stage biotechnology company pioneering first-in-class antibody-drug conjugates (ADCs) and antibodies targeting Claudin-1 (CLDN1) for oncology and multi-organ fibrosis. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alent…
Open positions
Chemist / Conjugation Expert
About this position The Chemist / Conjugation Expert acts as SME for the development, optimization, and scale-up of bioconjugation processes for our antibody-based therapeutic portfolio. As a key technical contributor,…